The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]
Yuebing Li, MD, PhD
Advertisement
Articles by Yuebing Li, MD, PhD
Since it was first discovered in the early 1900s, the therapeutic approaches to treating myasthenia gravis have changed significantly, with several proven treatment options.
Advertisement
Latest Updated Articles
Building the Myasthenia Gravis ArmamentariumPublished: August 11th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
2
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
3
This Week on NeurologyLive® — November 3, 2025
4
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
5
